FDA Approves Zepbound for Moderate-to-Severe Obstructive Sleep Apnea and Obesity
The recent FDA approval of Zepbound (tirzepatide), produced by Eli Lilly, marks a groundbreaking advancement in the management of moderate-to-severe obstructive sleep apnea (OSA) among adults with obesity. The announcement on December 20 signifies a pivotal moment in the landscape of sleep medicine, as it expands treatment options for patients